DeutschNewstral
Article
Bbarrons.com on 2019-12-06 15:38
Sage Therapeutics Stock Collapsed Thursday. Analysts Say It Has Fallen Enough.
Related news
- BSage Therapeutics Is Cratering Because Its Depression Treatment Failed In A Key Trialbarrons.com
- BSage Therapeutics Lays Off Staff to Save Cash After Failed Drug Trialbarrons.com
- BNeurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogenbarrons.com
- MFedEx stock has already fallen enough to price in weak outlook, analysts saymarketwatch.com
Sage Therapeutics surges on postpartum depression drug studyseattletimes.com
Sage Therapeutics sees modest results from tremor drug trialbizjournals.com
Does Sage Therapeutics' Failure Predict Its Future Results?Forbes- BSarepta Therapeutics Drops on Earnings. Why Analysts Remain Hopeful.barrons.com
- Weed dispensary Sage Naturals changes name after lawsuit by Sage Therapeuticsbizjournals.com
- MShares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rolloutmarketwatch.com
- Sage Therapeutics gains $220M in value as depression drug clears trial hurdlebizjournals.com
- Sage Therapeutics Takes Investors On A Wild Ride As CEO Talks Up Brain DrugsForbes
- MSage Therapeutics stock bounces 49% after positive results for depression treatmentmarketwatch.com
- Top former Alnylam exec Barry Greene named CEO of Sage Therapeuticsbizjournals.com
- BHow Sage Therapeutics Beaten-Down Stock Could Come Back2 min readbarrons.com
- New Drug Eases Postpartum Depression In Victory For Tiny Sage TherapeuticsForbes
- Sage Therapeutics to seek approval of postpartum depression drug after trial winbizjournals.com
- MSage Therapeutics shares surge 45% on positive trail of postpartum depression drugmarketwatch.com
- Five things you don’t know about Jeff Jonas, CEO of Sage Therapeuticsbizjournals.com